This section describes the characteristics of studies included in the analysis of pulmonary disease (COPD) based on the available randomized clinical trials (RCTs).

Type of studies: RCTs
Type of participants: COPD patients ≥40 years of age with FEV₁/FVC of <0.70 and FEV₁ percent predicted <80%
Exclusion: Patients with asthma or other respiratory or pulmonary diseases and other clinically significant diseases that may have affected treatment.
Type of intervention: Indacaterol 150 µg or 300 µg, fixed dose combinations of FOR/BUD and SAL/FP. Comparators included any of the interventions or placebo.
Type of outcome measures: Outcomes of interest included trough FEV₁ (reported predose values) at 12 weeks and 6 months, SGRQ total score at 6 months, and TDI total score at 6 months.
Result:

Table 1 Study characteristics for each study included in the network meta-analysis

| Source                        | Trial type   | Location                                                                             | Duration   | Active treatments            | Examples of key comorbidity exclusions                                                                                                                                                                                                                                                                                                                                                                                                                                        | Ethnicityᵃ                                            |
|:------------------------------|:-------------|:-------------------------------------------------------------------------------------|:-----------|:-----------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------|
| Hanania et al¹²               | RCT, DB, MC  | 76 centers; US                                                                       | 24 weeks   | SAL/FP; <br>50/250 µg; BID   | Patients with asthma and significant medical disorders                                                                                                                                                                                                                                                                                                                                                                                                                      | White: 91%–96% <br>Black: 3%–5% <br>Asian/other: 2%–3%    |
| Barnes et al¹⁴                | RCT, DB, MC  | NR                                                                                   | 13 weeks   | SAL/FP; <br>50/500 µg; BID   | NR                                                                                                                                                                                                                                                                                                                                                                                                                                                          | White: 99%–100% <br>Asian: 0%–1% <br>NR                 |
| Calverley et al¹⁵             | RCT, DB, MC  | 196 centers; 25 countries <br>in Europe including Russia, Australia, <br>New Zealand, Canada, South Africa | 52 weeks   | SAL/FP; <br>50/500 µg; BID   | Patients with other respiratory disorders                                                                                                                                                                                                                                                                                                                                                                                                                   | NR                                                      |
| Calverley et al¹⁶             | RCT, DB, MC  | 444 centers; 42 countries                                                            | 3 years    | SAL/FP; <br>50/500 µg; BID   | Patients with asthma, other respiratory disorders, or other diagnosis that may interfere with treatment                                                                                                                                                                                                                                                                                                                                                         | United States: 23% <br>Europe: 50% <br>Asia: 12%–13% <br>Other: 15%     |
| Mahler et al¹⁹                | RCT, DB, MC  | 65 centers; US                                                                       | 24 weeks   | SAL/FP; <br>50/500 µg; BID   | Patients with asthma and/or significant medical disorders (emphysema: 74%–78%)                                                                                                                                                                                                                                                                                                                                                                                 | White: 92%–95% <br>Black: 4%–6% <br>Asian/other: 1%–2%    |
| Zheng et al²²                 | RCT, DB, MC  | 12 centers; China                                                                    | 24 weeks   | SAL/FP; <br>50/500 µg; BID   | Patients with other respiratory disorders and/or significant medical disorders                                                                                                                                                                                                                                                                                                                                                                                 | 100% Chinese                                            |
| Calverley et al¹⁷             | RCT, DB, MC  | 109 centers; 15 countries <br>in Europe, Brazil, South Africa <br>and Asia (China, Malaysia, Taiwan, <br>and Thailand) | 52 weeks   | FOR/BUD; <br>9/320 µg; BID   | Patients with history of asthma, seasonal allergic rhinitis prior the age of 40 years, relevant cardiovascular disorders or significant disorder                                                                                                                                                                                                                                                                                                                            | NR                                                      |
| Rennard et al²⁰               | RCT, DB, DD, MC | 237 centers; US and Mexico                                                           | 52 weeks   | FOR/BUD; <br>9/160 µg; BID; <br>FOR/BUD; <br>9/320 µg; BID   | Patients with history of asthma, seasonal allergic rhinitis prior the age of 40 years, relevant cardiovascular disorders or other respiratory tract disorders                                                                                                                                                                                                                                                                                                                 | White: 92.5% <br>Black: 2.6% <br>Asian: 0.2% <br>Other: 4.7%      |
| Tashkin et al²¹               | RCT, DB, DD, MC | 194 centers; US, Czech Republic, <br>The Netherlands, Poland and <br>South Africa     | 26 weeks   | FOR/BUD; 9/160 µg; <br>BID; FOR/BUD; <br>9/320 µg; BID   | Patients with history of asthma, seasonal allergic rhinitis before the age of 40 years, any relevant cardiovascular disorders or other respiratory tract disorder                                                                                                                                                                                                                                                                                                                                                        | White: 92%–93% <br>Black: 2%–3% <br>Asian: 0%–1% <br>Other: 4%–6%     |
| Dahl et al²⁷ <br>(B2334)²⁷ <br>Non-ICS     | RCT, DB, DD, MC  | 240 centers; Europe and Russia, <br>Argentina, Chile, Colombia, Ecuador, <br>Egypt, Israel, Peru, South Korea   | 52 weeks   | IND; 300 µg; OD              | Patients with concomitant pulmonary disease, type 1 diabetes, a history of asthma, or significant condition⁴                                                                                                                                                                                                                                                                                                                                                                   | Caucasian: 92%–94% <br>Black: 0% <br>Asian: 2% <br>Other: 5%–6%       |
| Donohu et al²⁵ <br>(B2335)²⁵ <br>Non-ICS    | RCT, PC, DB, DD, MC; <br>2 stage adaptive seamless   | 334 centers; Argentina, <br>Canada, Germany, India, <br>Italy, Korea, Spain, Sweden, <br>Turkey, Taiwan, US                           | 26 weeks   | IND; 150 µg; OD; <br>IND; 300 µg; OD   | Patients with concomitant pulmonary disease, type 1 diabetes, a history of asthma, or significant condition⁴                                                                                                                                                                                                                                                                                                                                                                   | Caucasian: 79%–82% <br>Black: 2%–3% <br>Asian: 13%–19% <br>Other: 0%–1%   |
| Kornmann et al²⁴ <br>(B2336)²⁴ <br>Non-ICS  | RCT, DB, DD, MC  | 142 centers                                                                          | 26 weeks   | IND; 150 µg; OD              | Patients with concomitant pulmonary disease, type 1 diabetes, a history of asthma, or significant condition⁴                                                                                                                                                                                                                                                                                                                                                                   | Caucasian: 75%–78% <br>Black: 0% <br>Asian: 16%–17% <br>Other: 7%–8%     |
| Feldman et al²⁶ <br>(B2346)²⁶ <br>Non-ICS  | RCT, DB, DD, MC  | 103 centers; US, Australia/ <br>New Zealand, Belgium                                | 12 weeks   | IND; 150 µg; OD              | Patients with a history of asthma or any significant pulmonary disease or cardiovascular abnormality                                                                                                                                                                                                                                                                                                                                                                        | Caucasian: 92%–93% <br>Black: 5%–6% <br>Asian: 0% <br>Other: 2%         |
| B2333¹⁸ <br>Non-ICS           | RCT, DB, MC  | Multiple centers; China and India                                                    | 26 weeks   | IND; 150 µg; OD              | Patients with concomitant pulmonary disease, a history of asthma, type 1 diabetes, or clinically significant condition⁴                                                                                                                                                                                                                                                                                                                                                        | Caucasian: 4%–5% <br>Asian: 95% <br>(Chinese 89%–90%)     |
| B1302²³ <br>Non-ICS           | RCT, DB, MC  | 73 centers; Japan, Taiwan, Korea, <br>India, Hong Kong, and Singapore                  | 12 weeks   | IND; 150 µg; OD; <br>IND; 300 µg; OD   | Patients with concomitant pulmonary disease, a history of asthma, type 1 diabetes, or clinically significant condition⁴                                                                                                                                                                                                                                                                                                                                                        | Asian: 100% <br>(Japanese 43%–45%, <br>Chinese 15%–17%, <br>Korean 28%–30%) |

Table 2 Key baseline patient characteristics for each study included in network meta-analysis

| Source           | Treatment     | Randomized no. | % male | Mean age | % current smokers | % severe or very severe | FEV₁        | FVC        | BDI        | SGRQ        |
|:-----------------|:--------------|:---------------|:-------|:---------|:------------------|:------------------------|:------------|:-----------|:-----------|:------------|
| Hanania et al¹²  | Placebo       | 185            | 68%    | 65       | 47%               | 75%                     | 1.29 (0.43) | NR         | 5.7 (NR)   | CRDQ = 84.8   |
|                  | SAL/FP 50/250 | 178            | 61%    | 63       | 43%               | 79%                     | 1.25 (0.40) | NR         | 6.1 (NR)   | CRDQ = 84.1   |
| Barnes et al¹⁴   | Placebo       | 73             | 70%    | 64       | 59%               | 19%                     | 1.68 (0.47) | NR         | NR         | NR          |
|                  | SAL/FP 50/500 | 67             | 82%    | 63       | 63%               | 19%                     | 1.67 (0.44) | NR         | NR         | NR          |
| Calverley et al¹⁵ | Placebo       | 361            | 75%    | 63       | 47%               | 66%                     | 1.27 (0.47) | 2.50 (0.80) | NR         | 47.1 (16.5) |
|                  | SAL/FP 50/500 | 358            | 75%    | 63       | 52%               | 64%                     | 1.31 (0.53) | 2.54 (0.84) | NR         | 47.1 (15.7) |
| Calverley et al¹⁶ | Placebo       | 1545           | 76%    | 65       | 43%               | 68%                     | 1.12 (0.40) | NR         | 49.0 (17.4) |
|                  | SAL/FP 50/500 | 1546           | 75%    | 65       | 43%               | 68%                     | 1.12 (0.40) | NR         | 48.9 (17.4) |
| Mahler et al¹⁹   | Placebo       | 181            | 75%    | 64       | 54%               | 77%                     | 1.32 (NR)   | NR         | 5.6 (NR)   | CRDQ = 86.2   |
|                  | SAL/FP 50/500 | 165            | 62%    | 62       | 46%               | 77%                     | 1.27 (NR)   | NR         | 6.2 (NR)   | CRDQ = 87.1   |
| Zheng et al²²    | Placebo       | 148            | 86%    | 67       | 23%               | 60%                     | 1.03 (NR)   | NR         | NR         | 44.5 (NR)   |
|                  | SAL/FP 50/500 | 297            | 91%    | 66       | 21%               | 60%                     | 1.06 (NR)   | NR         | NR         | 44.8 (NR)   |
| Calverley et al¹⁷ | Placebo       | 256            | 75%    | 65       | 30%               | 92%                     | 0.98 (0.33) | NR         | NR         | 48.0 (19.0) |
|                  | FOR/BUD 9/320 | 254            | 78%    | 64       | 33%               | 92%                     | 0.98 (0.33) | NR         | NR         | 48.0 (18.0) |
| Rennard et al²⁰  | Placebo       | 481            | 65%    | 63       | 44%               | 81%                     | 1.10 (0.40) | NR         | BCSS: 2.1  | 54.7 (16.1) |
|                  | FOR/BUD 9/160 | 494            | 63%    | 64       | 42%               | 83%                     | 1.00 (0.40) | NR         | BCSS: 2.2  | 55.7 (16.7) |
|                  | FOR/BUD 9/320 | 494            | 62%    | 63       | 39%               | 83%                     | 1.00 (0.40) | NR         | BCSS: 2.2  | 54.6 (17.4) |
| Tashkin et al²¹  | Placebo       | 300            | 69%    | 63       | 40%               | 76%                     | 1.08 (0.38) | NR         | BCSS: 2.0  | 55.6 (17.0) |
|                  | FOR/BUD 9/160 | 281            | 64%    | 64       | 45%               | 82%                     | 1.04 (0.38) | NR         | BCSS: 2.0  | 55.5 (16.3) |
|                  | FOR/BUD 9/320 | 277            | 68%    | 63       | 44%               | 82%                     | 1.04 (0.42) | NR         | BCSS: 2.1  | 56.5 (15.8) |
| B2334²⁷; non-ICS | Placebo       | 180            | 83%    | 64       | 46%               | 38%                     | 1.40 (0.50) | 2.77 (0.81) | 6.7 (2.3)  | 43.4 (17.5) |
|                  | IND 300       | 165            | 82%    | 64       | 46%               | 44%                     | 1.32 (0.42) | 2.72 (0.85) | 6.5 (2.0)  | 46.3 (17.5) |
| B2335²⁵; non-ICS | Placebo       | 226            | 60%    | 63       | 47%               | 32%                     | 1.39 (0.51) | 2.60 (0.79) | 6.5 (2.4)  | 46.7 (17.5) |
|                  | IND 150       | 240            | 62%    | 62       | 52%               | 33%                     | 1.43 (0.53) | 2.65 (0.78) | 6.9 (2.4)  | 43.2 (19.1) |
|                  | IND 300       | 241            | 66%    | 63       | 50%               | 34%                     | 1.41 (0.54) | 2.72 (0.84) | 6.7 (2.3)  | 44.0 (18.7) |

<PAGE>116
```
Checking the PICO structure. The phrase "pulmonary disease (COPD) based on the available randomized clinical trials (RCTs)." is part of the overall context. The 'Type of studies' itself is "RCTs". I should make this clear. The current structure is good: an introductory sentence, then key-value pairs.

The Korean sidebar text "PICO 및 근거표" appears to be the heading for the whole section.
The content seems to be a description of the PICO elements of the included studies.

Let's verify table content extraction, especially multi-line cells and "NR" values.
-   Table 1:
    -   Location for Calverley et al¹⁵: "196 centers; 25 countries in Europe including Russia, Australia, New Zealand, Canada, South Africa" - Looks correct.
    -   Location for Calverley et al¹⁶: "444 centers; 42 countries" - Correct.
    -   Location for Calverley et al¹⁷: "109 centers; 15 countries in Europe, Brazil, South Africa and Asia (China, Malaysia, Taiwan, and Thailand)" - Correct.
    -   Location for Tashkin et al²¹: "194 centers; US, Czech Republic, The Netherlands, Poland and South Africa" - Correct.
    -   Location for Dahl et al²⁷: "240 centers; Europe and Russia, Argentina, Chile, Colombia, Ecuador, Egypt, Israel, Peru, South Korea" - Correct.
    -   Location for Donohu et al²⁵: "334 centers; Argentina, Canada, Germany, India, Italy, Korea, Spain, Sweden, Turkey, Taiwan, US" - Correct.
    -   Location for B1302²³: "73 centers; Japan, Taiwan, Korea, India, Hong Kong, and Singapore" - Correct.
    -   Ethnicity for Hanania et al¹²: "White: 91%–96% Black: 3%–5% Asian/other: 2%–3%" - Correct.
    -   Ethnicity for Barnes et al¹⁴: "White: 99%–100% Asian: 0%–1% NR" - Correct.
    -   Ethnicity for Calverley et al¹⁶: "United States: 23% Europe: 50% Asia: 12%–13% Other: 15%" - Correct.
    -   Ethnicity for Mahler et al¹⁹: "White: 92%–95% Black: 4%–6% Asian/other: 1%–2%" - Correct.
    -   Ethnicity for Tashkin et al²¹: "White: 92%–93% Black: 2%–3% Asian: 0%–1% Other: 4%–6%" - Correct.
    -   Ethnicity for Dahl et al²⁷: "Caucasian: 92%–94% Black: 0% Asian: 2% Other: 5%–6%" - Correct.
    -   Ethnicity for Donohu et al²⁵: "Caucasian: 79%–82% Black: 2%–3% Asian: 13%–19% Other: 0%–1%" - Correct.
    -   Ethnicity for Kornmann et al²⁴: "Caucasian: 75%–78% Black: 0% Asian: 16%–17% Other: 7%–8%" - Correct.
    -   Ethnicity for Feldman et al²⁶: "Caucasian: 92%–93% Black: 5%–6% Asian: 0% Other: 2%" - Correct.
    -   Ethnicity for B2333¹⁸: "Caucasian: 4%–5% Asian: 95% (Chinese 89%–90%)" - Correct.
    -   Ethnicity for B1302²³: "Asian: 100% (Japanese 43%–45%, Chinese 15%–17%, Korean 28%–30%)" - Correct.

-   Table 2:
    -   FEV₁ for Hanania et al¹² Placebo: "1.29 (0.43)" - Correct.
    -   SGRQ for Hanania et al¹² Placebo: "CRDQ = 84.8" - Correct.
    -   SGRQ for Mahler et al¹⁹ Placebo: "CRDQ = 86.2" - Correct.
    -   Many NR values - Correctly transcribed.
    -   BDI/SGRQ for Rennard et al²⁰ and Tashkin et al²¹: "BCSS: X.X" - Correct.

The structure looks good. The "PICO 및 근거표" heading is an appropriate markdown for a section header. The PICO elements are clearly defined. The two tables are correctly formatted. The page number is at the bottom.### PICO 및 근거표

This section describes the characteristics of studies included in the analysis of pulmonary disease (COPD) based on the available randomized clinical trials (RCTs).

Type of studies: RCTs
Type of participants: COPD patients ≥40 years of age with FEV₁/FVC of <0.70 and FEV₁ percent predicted <80%
Exclusion: Patients with asthma or other respiratory or pulmonary diseases and other clinically significant diseases that may have affected treatment.
Type of intervention: Indacaterol 150 µg or 300 µg, fixed dose combinations of FOR/BUD and SAL/FP. Comparators included any of the interventions or placebo.
Type of outcome measures: Outcomes of interest included trough FEV₁ (reported predose values) at 12 weeks and 6 months, SGRQ total score at 6 months, and TDI total score at 6 months.
Result:

Table 1 Study characteristics for each study included in the network meta-analysis

| Source                        | Trial type       | Location                                                                             | Duration   | Active treatments            | Examples of key comorbidity exclusions                                                                                                                                                                                                                                                                                                                                                                                                                                        | Ethnicityᵃ                                            |
|:------------------------------|:-----------------|:-------------------------------------------------------------------------------------|:-----------|:-----------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------|
| Hanania et al¹²               | RCT, DB, MC      | 76 centers; US                                                                       | 24 weeks   | SAL/FP;<br>50/250 µg; BID    | Patients with asthma and significant medical disorders                                                                                                                                                                                                                                                                                                                                                                                                                      | White: 91%–96%<br>Black: 3%–5%<br>Asian/other: 2%–3%    |
| Barnes et al¹⁴                | RCT, DB, MC      | NR                                                                                   | 13 weeks   | SAL/FP;<br>50/500 µg; BID    | NR                                                                                                                                                                                                                                                                                                                                                                                                                                                          | White: 99%–100%<br>Asian: 0%–1%<br>NR                 |
| Calverley et al¹⁵             | RCT, DB, MC      | 196 centers; 25 countries<br>in Europe including Russia, Australia,<br>New Zealand, Canada, South Africa | 52 weeks   | SAL/FP;<br>50/500 µg; BID    | Patients with other respiratory disorders                                                                                                                                                                                                                                                                                                                                                                                                                   | NR                                                      |
| Calverley et al¹⁶             | RCT, DB, MC      | 444 centers; 42 countries                                                            | 3 years    | SAL/FP;<br>50/500 µg; BID    | Patients with asthma, other respiratory disorders, or other diagnosis that may interfere with treatment                                                                                                                                                                                                                                                                                                                                                         | United States: 23%<br>Europe: 50%<br>Asia: 12%–13%<br>Other: 15%     |
| Mahler et al¹⁹                | RCT, DB, MC      | 65 centers; US                                                                       | 24 weeks   | SAL/FP;<br>50/500 µg; BID    | Patients with asthma and/or significant medical disorders (emphysema: 74%–78%)                                                                                                                                                                                                                                                                                                                                                                                 | White: 92%–95%<br>Black: 4%–6%<br>Asian/other: 1%–2%    |
| Zheng et al²²                 | RCT, DB, MC      | 12 centers; China                                                                    | 24 weeks   | SAL/FP;<br>50/500 µg; BID    | Patients with other respiratory disorders and/or significant medical disorders                                                                                                                                                                                                                                                                                                                                                                                 | 100% Chinese                                            |
| Calverley et al¹⁷             | RCT, DB, MC      | 109 centers; 15 countries<br>in Europe, Brazil, South Africa<br>and Asia (China, Malaysia, Taiwan,<br>and Thailand) | 52 weeks   | FOR/BUD;<br>9/320 µg; BID    | Patients with history of asthma, seasonal allergic rhinitis prior the age of 40 years, relevant cardiovascular disorders or significant disorder                                                                                                                                                                                                                                                                                                                            | NR                                                      |
| Rennard et al²⁰               | RCT, DB, DD, MC  | 237 centers; US and Mexico                                                           | 52 weeks   | FOR/BUD;<br>9/160 µg; BID;<br>FOR/BUD;<br>9/320 µg; BID    | Patients with history of asthma, seasonal allergic rhinitis prior the age of 40 years, relevant cardiovascular disorders or other respiratory tract disorders                                                                                                                                                                                                                                                                                                                 | White: 92.5%<br>Black: 2.6%<br>Asian: 0.2%<br>Other: 4.7%      |
| Tashkin et al²¹               | RCT, DB, DD, MC  | 194 centers; US, Czech Republic,<br>The Netherlands, Poland and<br>South Africa     | 26 weeks   | FOR/BUD; 9/160 µg;<br>BID; FOR/BUD;<br>9/320 µg; BID    | Patients with history of asthma, seasonal allergic rhinitis before the age of 40 years, any relevant cardiovascular disorders or other respiratory tract disorder                                                                                                                                                                                                                                                                                                                                                        | White: 92%–93%<br>Black: 2%–3%<br>Asian: 0%–1%<br>Other: 4%–6%     |
| Dahl et al²⁷<br>(B2334)²⁷<br>Non-ICS     | RCT, DB, DD, MC  | 240 centers; Europe and Russia,<br>Argentina, Chile, Colombia, Ecuador,<br>Egypt, Israel, Peru, South Korea   | 52 weeks   | IND; 300 µg; OD              | Patients with concomitant pulmonary disease, type 1 diabetes, a history of asthma, or significant condition⁴                                                                                                                                                                                                                                                                                                                                                                   | Caucasian: 92%–94%<br>Black: 0%<br>Asian: 2%<br>Other: 5%–6%       |
| Donohu et al²⁵<br>(B2335)²⁵<br>Non-ICS    | RCT, PC, DB, DD, MC;<br>2 stage adaptive seamless   | 334 centers; Argentina,<br>Canada, Germany, India,<br>Italy, Korea, Spain, Sweden,<br>Turkey, Taiwan, US                           | 26 weeks   | IND; 150 µg; OD;<br>IND; 300 µg; OD   | Patients with concomitant pulmonary disease, type 1 diabetes, a history of asthma, or significant condition⁴                                                                                                                                                                                                                                                                                                                                                                   | Caucasian: 79%–82%<br>Black: 2%–3%<br>Asian: 13%–19%<br>Other: 0%–1%   |
| Kornmann et al²⁴<br>(B2336)²⁴<br>Non-ICS  | RCT, DB, DD, MC  | 142 centers                                                                          | 26 weeks   | IND; 150 µg; OD              | Patients with concomitant pulmonary disease, type 1 diabetes, a history of asthma, or significant condition⁴                                                                                                                                                                                                                                                                                                                                                                   | Caucasian: 75%–78%<br>Black: 0%<br>Asian: 16%–17%<br>Other: 7%–8%     |
| Feldman et al²⁶<br>(B2346)²⁶<br>Non-ICS  | RCT, DB, DD, MC  | 103 centers; US, Australia/<br>New Zealand, Belgium                                | 12 weeks   | IND; 150 µg; OD              | Patients with a history of asthma or any significant pulmonary disease or cardiovascular abnormality                                                                                                                                                                                                                                                                                                                                                                        | Caucasian: 92%–93%<br>Black: 5%–6%<br>Asian: 0%<br>Other: 2%         |
| B2333¹⁸<br>Non-ICS           | RCT, DB, MC      | Multiple centers; China and India                                                    | 26 weeks   | IND; 150 µg; OD              | Patients with concomitant pulmonary disease, a history of asthma, type 1 diabetes, or clinically significant condition⁴                                                                                                                                                                                                                                                                                                                                                        | Caucasian: 4%–5%<br>Asian: 95%<br>(Chinese 89%–90%)     |
| B1302²³<br>Non-ICS           | RCT, DB, MC      | 73 centers; Japan, Taiwan, Korea,<br>India, Hong Kong, and Singapore                  | 12 weeks   | IND; 150 µg; OD;<br>IND; 300 µg; OD   | Patients with concomitant pulmonary disease, a history of asthma, type 1 diabetes, or clinically significant condition⁴                                                                                                                                                                                                                                                                                                                                                        | Asian: 100%<br>(Japanese 43%–45%,<br>Chinese 15%–17%,<br>Korean 28%–30%) |

Table 2 Key baseline patient characteristics for each study included in network meta-analysis

| Source            | Treatment     | Randomized no. | % male | Mean age | % current smokers | % severe or very severe | FEV₁        | FVC        | BDI        | SGRQ        |
|:------------------|:--------------|:---------------|:-------|:---------|:------------------|:------------------------|:------------|:-----------|:-----------|:------------|
| Hanania et al¹²   | Placebo       | 185            | 68%    | 65       | 47%               | 75%                     | 1.29 (0.43) | NR         | 5.7 (NR)   | CRDQ = 84.8   |
|                   | SAL/FP 50/250 | 178            | 61%    | 63       | 43%               | 79%                     | 1.25 (0.40) | NR         | 6.1 (NR)   | CRDQ = 84.1   |
| Barnes et al¹⁴    | Placebo       | 73             | 70%    | 64       | 59%               | 19%                     | 1.68 (0.47) | NR         | NR         | NR          |
|                   | SAL/FP 50/500 | 67             | 82%    | 63       | 63%               | 19%                     | 1.67 (0.44) | NR         | NR         | NR          |
| Calverley et al¹⁵ | Placebo       | 361            | 75%    | 63       | 47%               | 66%                     | 1.27 (0.47) | 2.50 (0.80) | NR         | 47.1 (16.5) |
|                   | SAL/FP 50/500 | 358            | 75%    | 63       | 52%               | 64%                     | 1.31 (0.53) | 2.54 (0.84) | NR         | 47.1 (15.7) |
| Calverley et al¹⁶ | Placebo       | 1545           | 76%    | 65       | 43%               | 68%                     | 1.12 (0.40) | NR         | NR         | 49.0 (17.4) |
|                   | SAL/FP 50/500 | 1546           | 75%    | 65       | 43%               | 68%                     | 1.12 (0.40) | NR         | NR         | 48.9 (17.4) |
| Mahler et al¹⁹    | Placebo       | 181            | 75%    | 64       | 54%               | 77%                     | 1.32 (NR)   | NR         | 5.6 (NR)   | CRDQ = 86.2   |
|                   | SAL/FP 50/500 | 165            | 62%    | 62       | 46%               | 77%                     | 1.27 (NR)   | NR         | 6.2 (NR)   | CRDQ = 87.1   |
| Zheng et al²²     | Placebo       | 148            | 86%    | 67       | 23%               | 60%                     | 1.03 (NR)   | NR         | NR         | 44.5 (NR)   |
|                   | SAL/FP 50/500 | 297            | 91%    | 66       | 21%               | 60%                     | 1.06 (NR)   | NR         | NR         | 44.8 (NR)   |
| Calverley et al¹⁷ | Placebo       | 256            | 75%    | 65       | 30%               | 92%                     | 0.98 (0.33) | NR         | NR         | 48.0 (19.0) |
|                   | FOR/BUD 9/320 | 254            | 78%    | 64       | 33%               | 92%                     | 0.98 (0.33) | NR         | NR         | 48.0 (18.0) |
| Rennard et al²⁰   | Placebo       | 481            | 65%    | 63       | 44%               | 81%                     | 1.10 (0.40) | NR         | BCSS: 2.1  | 54.7 (16.1) |
|                   | FOR/BUD 9/160 | 494            | 63%    | 64       | 42%               | 83%                     | 1.00 (0.40) | NR         | BCSS: 2.2  | 55.7 (16.7) |
|                   | FOR/BUD 9/320 | 494            | 62%    | 63       | 39%               | 83%                     | 1.00 (0.40) | NR         | BCSS: 2.2  | 54.6 (17.4) |
| Tashkin et al²¹   | Placebo       | 300            | 69%    | 63       | 40%               | 76%                     | 1.08 (0.38) | NR         | BCSS: 2.0  | 55.6 (17.0) |
|                   | FOR/BUD 9/160 | 281            | 64%    | 64       | 45%               | 82%                     | 1.04 (0.38) | NR         | BCSS: 2.0  | 55.5 (16.3) |
|                   | FOR/BUD 9/320 | 277            | 68%    | 63       | 44%               | 82%                     | 1.04 (0.42) | NR         | BCSS: 2.1  | 56.5 (15.8) |
| B2334²⁷; non-ICS  | Placebo       | 180            | 83%    | 64       | 46%               | 38%                     | 1.40 (0.50) | 2.77 (0.81) | 6.7 (2.3)  | 43.4 (17.5) |
|                   | IND 300       | 165            | 82%    | 64       | 46%               | 44%                     | 1.32 (0.42) | 2.72 (0.85) | 6.5 (2.0)  | 46.3 (17.5) |
| B2335²⁵; non-ICS  | Placebo       | 226            | 60%    | 63       | 47%               | 32%                     | 1.39 (0.51) | 2.60 (0.79) | 6.5 (2.4)  | 46.7 (17.5) |
|                   | IND 150       | 240            | 62%    | 62       | 52%               | 33%                     | 1.43 (0.53) | 2.65 (0.78) | 6.9 (2.4)  | 43.2 (19.1) |
|                   | IND 300       | 241            | 66%    | 63       | 50%               | 34%                     | 1.41 (0.54) | 2.72 (0.84) | 6.7 (2.3)  | 44.0 (18.7) |

<PAGE>116